Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multi-Center, Open-Label, Single-Arm Phase II Trial of Bendamustine, Rituximab and the Second Generation BTK Inhibitor Acalabrutinib in Previously Untreated Waldenstrom's Macroglobulinemia

X
Trial Profile

A Multi-Center, Open-Label, Single-Arm Phase II Trial of Bendamustine, Rituximab and the Second Generation BTK Inhibitor Acalabrutinib in Previously Untreated Waldenstrom's Macroglobulinemia

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 11 Jul 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Acalabrutinib (Primary) ; Bendamustine (Primary) ; Rituximab (Primary) ; Rituximab (Primary)
  • Indications Waldenstrom's macroglobulinaemia
  • Focus Therapeutic Use
  • Acronyms BRAWM
  • Most Recent Events

    • 12 Dec 2023 Initial results(N=44) assessing efficacy and safety of Bendamustine, rituximab and acalabrutinib front-line therapy for Waldenstroms macroglobulinaemia (WM) presented at the 65th American Society of Hematology Annual Meeting and Exposition
    • 13 Dec 2022 Results (n=10) assessing efficacy and tolerability of Acalabrutinib with Bendamustine-Rituximab in First Line Waldenstroms Macroglobulinemia presented at the 64th American Society of Hematology Annual Meeting and Exposition
    • 17 Mar 2021 Status changed from not yet recruiting to recruiting.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top